Coronary Artery Disease Clinical Trial
Official title:
Mainz Registry of Flow-mediated Constriction
The goal of the flow-mediated constriction/ FMC-registry is to investigate whether the measurement of endothelial function using flow-mediated dilation and flow-mediated constriction provides on the presence of coronary atherosclerosis and on the prognosis of patients undergoing coronary angiography.
Coronary artery disease (CAD) is a lifelong process resulting from the interaction of many
risk factors, environmental influences, and genetic predisposition. Although the collection
of medical history and standard risk factors provides essential information, the existence of
complex interactions among different risk factors, risk modifications by medical therapy, and
inter-individual differences complicate these issues. In the light of these limitations,
alternative approaches have been sought, and the non-invasive assessment of endothelial
function has been proposed as a possible non-invasive and inexpensive endpoint that could
reflect the cumulative cardiovascular burden and/or the responsiveness to therapies at the
level of individual patients.
A total of 1000 consecutive patients undergoing elective coronary angiography will be
studied. Patients have chest pain on effort according to the American College of
Cardiology/American Heart Association 2007 Guidelines and/or a pathological exercise or
dobutamine stress test. Patients undergoing catheterization for any reason other than stable
(suspected) CAD (e.g. for hypertensive crisis associated with troponin elevation, or acute
coronary syndromes, valvular heart disease, congenital heart disease, cardiomyopathy, etc.)
will be excluded. Patients with known chronic inflammatory diseases, dialysis, or
decompensated/severe heart failure will be also excluded.
Blood samples will be drawn from all patients after a fasting period of at least 12 h and
will be examined with the use of routine laboratory methods for blood counts, lipid
parameters, C-reactive protein, renal and hepatic function. Coronary risk factors were
defined as: obesity (body mass index >30 kg/m2); age; smoking (or previous smoking);
hyperlipidaemia (total serum cholesterol >220 mg/dL and/or serum triglycerides >200 mg/dL);
hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg on two
consecutive seated measurements or therapy with antihypertensive medication); family history
(first-degree relatives with cardiovascular disease); diabetes mellitus (fasting serum
glucose levels >126 mg/dL or therapy with oral hypoglycaemic agents or insulin).
The methods employed for L-FMC/FMD (flow mediated dilation)'analysis in our laboratory have
been previously published (Gori Journal of the American College of Cardiology 2008). Briefly,
patients will be placed supine, the left arm immobilized, and L-FMC and FMD will be measured
using a Vivid 7 (General Electrics, Munich, Germany) ultrasound platform equipped with a 14
MHz matrix probe and a micrometric probe holder. Low-flow-mediated constriction corresponds
to the constriction observed during a 4.5 min occlusion of a pneumatic cuff placed distal to
the site of arterial diameter measurement. Flow-mediated dilation corresponds to the maximal
dilation observed in the 5 min following deflation of the cuff, i.e. during reactive
hyperaemia. Repeatability and reproducibility data of these methods have been recently
reported (intra-class correlation coefficient=0.68 and 0.80 for FMD and L-FMC, respectively).
All data will be acquired digitally and analysed in a randomized, blinded fashion prior to
coronary angiography by an investigator not aware of the clinical status of the patient,
using automatic dedicated software.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |